Telomir Pharmaceuticals, Inc. — Form 8-K
Filed September 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 38/100
What the filing says
Telomir Pharmaceuticals announced peer-reviewed publication in International Journal of Molecular Sciences demonstrating that Telomir-Zn improved visual function, restored retinal structure, and reduced oxidative stress in a zebrafish model of age-related macular degeneration. The study showed dose-dependent increases in telomeric DNA content, restoration of altered DNA methylation patterns, and potent inhibition of iron-dependent histone demethylases (KDM5B IC50=63 nM). Company maintains oncology focus; Phase 1/2 trial in triple-negative breast cancer remains primary development pathway.
Why this rating
Preclinical publication supports mechanism but does not alter current clinical program or near-term revenue. Modest validation of platform; company remains early-stage with market cap ~$18M.
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.